ArticleClinical and experimental medicine2025
Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome.
Nicholas L Hartog et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.